Suma Krishnan Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. This trade represents a 1.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Krystal Biotech Price Performance

KRYS stock traded up $12.17 during mid-day trading on Friday, hitting $234.13. 537,880 shares of the stock were exchanged, compared to its average volume of 326,125. The business has a fifty day moving average price of $197.92 and a 200 day moving average price of $162.51. The stock has a market capitalization of $6.79 billion, a price-to-earnings ratio of 35.10 and a beta of 0.48. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $234.65.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $1.54. The business had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of research analyst reports. Bank of America upped their price target on Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a report on Friday, October 17th. HC Wainwright reaffirmed a “buy” rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Monday, September 15th. Guggenheim set a $224.00 target price on shares of Krystal Biotech and gave the stock a “buy” rating in a report on Friday, October 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday. Finally, Citigroup boosted their target price on Krystal Biotech from $166.00 to $198.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $228.14.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KRYS. Soleus Capital Management L.P. raised its position in shares of Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Krystal Biotech by 173.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after purchasing an additional 365,304 shares during the last quarter. Braidwell LP raised its position in shares of Krystal Biotech by 81.6% in the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock valued at $100,045,000 after buying an additional 327,067 shares during the last quarter. Norges Bank acquired a new stake in shares of Krystal Biotech in the second quarter worth approximately $38,861,000. Finally, Nuveen LLC acquired a new stake in Krystal Biotech during the 1st quarter worth approximately $42,223,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).